Verrica Pharmaceuticals reports $14.3 million revenue in third quarter 2025
Verrica Pharmaceuticals Inc. reported total revenue of $14.3 million for the third quarter of 2025, including $3.6 million in YCANTH revenue and $10.7 million in license and collaboration revenue. For the nine months ended September 30, 2025, product revenue, net was $11.6 million, up from $6.3 million for the same period in 2024, primarily due to increased deliveries of YCANTH. License and collaboration revenue for the nine-month period was $18.9 million, compared to $1.0 million in the prior year, with $18.0 million attributed to milestone revenue from Torii. As of September 30, 2025, Verrica had $21.1 million in cash and cash equivalents. Recent business developments include positive feedback from the FDA regarding the Phase 3 program design for VP-315 in basal cell carcinoma, new data presented for VP-315, and a $10 million milestone payment received for the approval of YCANTH in Japan. The company also received supportive feedback from the European Medicines Agency for a Marketing Authorization Application filing for YCANTH for molluscum.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9576282-en) on November 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.